nivolumab,ipilimumab,cabozantinib
bms
['rcc,(-irccs),(-srcc),(-urcc)', 'cosmic313', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)']
it makes sense that the additive benefit of vegf to io therapy is less in imdc poor risk individuals with #rcc. good to know it wasn t due to poor tolerability in this group. #gu23 cosmic313 
A medical oncologist that specializes in and focuses his research on urologic cancers.